Health Canada has approved Neffy, the first needle-free treatment for severe allergic reactions stemming from insect stings, foods, or medications. This pocket-sized nasal spray offers an emergency option for anaphylaxis.
Developed by ALK-Abello Pharmaceuticals Inc. Canada, Neffy boasts a 30-month shelf life. Experts believe the nasal delivery will make patients more comfortable using epinephrine during emergencies, potentially increasing its utilization. It is anticipated to be available in Canadian pharmacies this summer.
This new option is welcomed by allergy specialists, who note that some individuals hesitate to use traditional needle-based injection devices. While EpiPen users often report the process is easier than expected, additional medication choices can lower barriers for many.
Neffy has the potential to treat many food allergies, offering an alternative to epinephrine autoinjectors. It addresses anaphylactic reactions triggered by allergens, though it does not treat the underlying allergy itself. More than three million Canadians report having a food allergy, with a significant number of children affected.
Specialists emphasize the importance of having accessible and insured medication options. The compact nature of Neffy is also seen as a significant advantage for children, offering a less conspicuous and more comfortable alternative to carrying traditional EpiPen devices.
Experts are optimistic about the introduction of similar products to the Canadian market, providing a crucial second option alongside existing injectors. Consultation with clinicians and specialists is recommended to determine the best course of action for managing allergy emergencies.